Celiprolol

Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences

Retrieved on: 
Wednesday, December 22, 2021
Celiprolol, Patient, UCD School of Medicine, Infection, MSUD, Emetine, Maple syrup urine disease, COL3A1, Acquisition, Metabolism, IVMS, COVID-19, III, Microdeletion syndrome, Vipul Ved Prakash, FDA, Pharmaceutical industry, Acer

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.

Key Points: 
  • Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
  • In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001.
  • For more information, visit www.acertx.com .

Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, UCD School of Medicine, MSUD, Maple syrup urine disease, Food and Drug Administration, GLOBE, Review, ACER, Flash, Celiprolol, Hypothalamus, Metabolism, Security (finance), Infection, Woman, NKB, Safety, Private Securities Litigation Reform Act, Drug development, Schizophrenia, Food, COL3A1, Patient, Therapy, Depression, Microdeletion syndrome, COVID-19, Flushing, VMS, Clinical trial, FDA, Emetine, Vipul Ved Prakash, Marketing, IVMS, Nasdaq, Annual report, Acquisition, Breast, Neurokinin B, III, Founder, Menopause, IND, Pharmaceutical industry

NEWTON, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its selective non-peptide neurokinin 3 receptor (NK3R) antagonist, ACER-801 (osanetant), for the potential treatment of induced Vasomotor Symptoms (iVMS).

Key Points: 
  • The trial is designed to evaluate the effect of ACER-801 at different doses, compared to placebo, on the frequency and severity of vasomotor symptoms associated with menopause.
  • Submission and clearance of our ACER-801 IND application is an important step toward the clinical development of our novel NK3R antagonist for treatment of iVMS," said Chris Schelling, Chief Executive Officer and Founder of Acer.
  • "This drug has been extensively studied, with over 1,200 individuals having received it in clinical trials for other non-iVMS indications.
  • VMS can also be induced (iVMS) by anti-androgen and anti-estrogen cancer therapies and surgical procedures that can lead to treatment non-compliance.

Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, November 19, 2021
State Administrative Expenses, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prescription Drug User Fee Act, Annual report, Woman, Pharmacokinetics, Lists of diseases, Metabolism, New Drug Application, ACER, GLOBE, Marketing, NDA, Microdeletion syndrome, Drug development, Food, Private Securities Litigation Reform Act, COL3A1, Security (finance), CEO, Drug discovery, Cancer, Founder, U.S. Securities and Exchange Commission, Emetine, Maple syrup urine disease, SPA, Hematology, File, Infection, IVMS, UCD, Collaboration, Research, Review, Urea, Celiprolol, Protein, Clinical trial, FDA, Therapy, USPTO, Patient, Patent, Safety, Acquisition, UCD School of Medicine, Mission statement, SEC, COVID-19, FDA Special Protocol Assessment, Nasdaq, MSUD, PDUFA, III, Ved Prakash Kamboj, No, Pharmaceutical industry

NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acers recent corporate developments.

Key Points: 
  • NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acers recent corporate developments.
  • This quarter was all about preparing regulatory filings to advance our pipeline products, said Chris Schelling, CEO and Founder of Acer.
  • Cash and cash equivalents were $14.2 million as of September 30, 2021, compared to $5.8 million as of December 31, 2020.
  • In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001.

Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Monday, August 30, 2021
Microdeletion syndrome, Acquisition, GLOBE, Acer, Vipul Ved Prakash, IVMS, UCD School of Medicine, Nasdaq, Metabolism, Therapy, Patient, Relief Therapeutics, Conference, ACER, III, FDA, Maple syrup urine disease, COVID-19, MSUD, Celiprolol, Emetine, COL3A1, Infection, Pharmaceutical industry

NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.

Key Points: 
  • NEWTON, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.
  • Available on demand beginning September 13, 2021 at 7 AM ET
    Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • In March 2021, Acer entered into a Collaboration and License Agreement with Relief Therapeutics for development and commercialization of ACER-001.
  • For more information, visit www.acertx.com .

Acer Therapeutics to Participate in March Virtual Investor Conferences

Retrieved on: 
Monday, March 1, 2021
Branches of biology, Health, Rare diseases, Collagen disease, Maple syrup urine disease, Celiprolol, Acer, Collagen, Sodium phenylbutyrate, Ehlers–Danlos syndromes, Ehlers, Maple

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.

Key Points: 
  • Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • Acers pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.
  • Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
  • For more information, visit www.acertx.com .

Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden

Retrieved on: 
Thursday, December 17, 2020
Collagen disease, Contortion, Celiprolol, Ureas, Anatomy, Branches of biology, Medical specialties, Ehlers

The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .

Key Points: 
  • The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .
  • Patients were followed for a median of 22 months (range 1-98 months) with a total follow up of 106 patient years.
  • Sixty-five percent of the patients reached the target dose of 400 mg and the medication was generally well tolerated.
  • Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, August 25, 2020
Branches of biology, Health, Clinical medicine, Rare diseases, Collagen disease, Celiprolol, Ureas, Maple syrup urine disease, Collagen, Sodium phenylbutyrate, Acer, Ehlers–Danlos syndromes

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.

Key Points: 
  • Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • Acers pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS).
  • Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
  • For more information, visit www.acertx.com .

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)

Retrieved on: 
Thursday, July 9, 2020
Legal, Professional services, Celiprolol, Ureas, Anatomy, Ehlers–Danlos syndrome, Collagen disease, Ehlers, Contortion, Acer Inc., Acer, Fiduciary, Organ systems, Medical specialties

Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934.
  • Acer is a pharmaceutical company that focuses on the development and commercialization of therapies for rare diseases.
  • One of its medications is EDVISO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome ("vEDS").
  • To help fund this research, Acer conducted two secondary public offerings in December 2017 and August 2018.

FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019

Retrieved on: 
Friday, August 30, 2019
Celiprolol, Ureas, Chemistry, Class action, Plaintiff, Physical sciences

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • On June 25, 2019, Acer issued a press release titled Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO (celiprolol) in vEDS Patients (the June 2019 Press Release).
  • If you suffered a loss in Acer you have until August 30, 2019 to request that the Court appoint you as lead plaintiff.
  • A lead plaintiff acts on behalf of all other class members in directing the litigation.

FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019

Retrieved on: 
Tuesday, August 27, 2019
Celiprolol, Ureas, Chemistry, Class action, Plaintiff, Physical sciences

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • On June 25, 2019, Acer issued a press release titled "Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO (celiprolol) in vEDS Patients" (the "June 2019 Press Release").
  • If you suffered a loss in Acer you have until August 30, 2019 to request that the Court appoint you as lead plaintiff.
  • A lead plaintiff acts on behalf of all other class members in directing the litigation.